WVENasdaqPharmaceutical PreparationsFiscal year ends December 31

Wave Life Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$3.17+0.04 (+1.28%)

Close on Oct 19, 2026

Market cap: $646.71M
P/E (TTM): –
Dividend yield: –

Wave Life Sciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	43	108	113	3.65	41	20	16	14	3.89	1.09	0.15	–	–
Research & Development	183	160	130	116	122	131	175	134	79	41	9.06	2.40	1.92
General & Administrative	75	59	51	51	46	43	49	40	27	16	10	3.00	1.65
Operating Expenses	258	219	181	166	168	173	224	174	106	57	19	5.39	3.57
Operating Income	-215	-110	-68	-163	-127	-153	-208	-160	-102	-56	-19	-5.39	-3.57
Interest & Investment Income	10	10	7.93	1.57	0.03	0.57	–	–	–	–	–	–	–
Other Non-Operating Income	11	13	9.81	1.58	4.57	2.63	15	13	1.25	0.54	0.14	0.25	-0.07
Asset Impairment Charges	–	–	–	–	–	–	–	–	0	0	0	–	–
Gain (Loss) on Sale of Assets	–	–	–	-0.01	–	–	–	-0.04	-0.21	–	–	-0.01	–
Pretax Income	-204	-97	-58	-161	-122	-151	-194	-147	-101	-55	-19	-5.15	-3.65
Income Tax Expense	0	0	-0.68	0.68	-0.20	-0.84	0	0.07	0.84	0.48	0.04	0.08	-0.33
Net Income incl. Noncontrolling Interests	-204	-97	-58	-162	-122	-150	-194	-147	-102	-56	–	–	–
Net Income	-204	-97	-58	-162	-122	-150	-194	-147	-102	-56	-19	-5.23	-3.32
Net Income to Common	-204	-97	-58	-162	-122	-150	-194	-147	-102	-56	-19	-5.23	-3.32
EPS (Basic)(per share)	-1.21	-0.70	-0.54	-2.05	-2.36	-3.82	-5.72	-5.06	-3.85	-2.44	-1.83	-1.34	-1.90
EPS (Diluted)(per share)	-1.21	-0.70	-0.54	-2.05	-2.36	-3.82	-5.72	-5.06	-3.85	-2.44	-1.83	-1.34	-1.90
Shares Outstanding (Basic, Weighted)(shares)	169	138	106	79	52	39	34	29	27	23	11	3.91	1.74
Shares Outstanding (Diluted, Weighted)(shares)	169	138	106	79	52	39	34	29	27	23	11	3.91	1.74
EBITDA	–	–	–	–	–	–	–	–	-100	-55	-19	-5.11	-3.30
Net Interest Income	–	–	–	–	–	–	–	–	–	–	0.09	-0.01	-0.11

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -510.0%
Net margin: -473.9%
Return on equity, FY2025: -56.2%

Financial strength

Current ratio: 9.99
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 724.2%

Valuation

P/E ratio: –
Price to sales: 15.14
Price to book: 1.43
Dividend yield: –